

Publications for Harriet Gee

2018

Pajic, M., Froio, D., Daly, S., Doculara, L., Millar, E., Graham, P., Drury, A., Steinmann, A., de Bock, C., O'Toole, S., Gee, H., et al (2018). miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. *Cancer Research*, 78(2), 501-515. [More Information]

Lamichhane, S., Thachil, T., De Ieso, P., Gee, H., Moss, S., Milic, N. (2018). Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Disease Markers*, 2018, 1-17. [More Information]

2016

Gee, H., Bignell, F., Odgers, D., Gill, S., Martin, D., Toohey, J., Carroll, S. (2016). In vivo dosimetric impact of breast tissue expanders on post-mastectomy radiotherapy. *Journal of Medical Imaging and Radiation Oncology*, 60(1), 138-145. [More Information]

Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warriar, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. *Histopathology*, 69(1), 25-34. [More Information]

Zhang, X., Gee, H., Rose, B., Lee, C., Clark, J., Elliott, M., Gamble, J., Cairns, M., Harris, A., Khoury, S., et al (2016). Regulation of the tumour suppressor PDCD4 by miR-499 and miR-21 in oropharyngeal cancers. *BMC Cancer*, 16(1), 1-11. [More Information]

2015

Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. *International Journal of Radiation Oncology Biology Physics*, 93(5), 1104-1114. [More Information]

2014

Gee, H., Ivan, C., Calin, G., Ivan, M. (2014). HypoxamiRs and Cancer: From Biology to Targeted Therapy. *Antioxidants & Redox Signaling*, 21(8), 1220-1238. [More Information]

2013

Kumar, K., Wigfield, S., Gee, H., Devlin, C., Singleton, D., Li, J., Buffa, F., Huffman, M., Sinn, A., Silver, J., et al (2013). Dichloroacetate reverses the hypoxic adaptation to

bevacizumab and enhances its antitumor effects in mouse xenografts. *Journal of Molecular Medicine*, 91(6), 749-758. [More Information]

2012

Gee, H., Hruby, G. (2012). Update on the Management of Merkel Cell Carcinoma. *Cancer Forum*, 36(3), 1-5.

2011

Buffa, F., Camps, C., Winchester, L., Snell, C., Gee, H., Sheldon, H., Taylor, M., Harris, A., Ragoussis, J. (2011). microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. *Cancer Research*, 71(17), 5635-5645. [More Information]

Gee, H., Buffa, F., Camps, C., Ramachandran, A., Leek, R., Taylor, M., Patil, M., Sheldon, H., Betts, G., Homer, J., et al (2011). The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. *British Journal of Cancer*, 104(7), 1168-1177. [More Information]

2010

Gee, H., Camps, C., Buffa, F., Patiar, S., Winter, S., Betts, G., Homer, J., Corbridge, R., Cox, G., West, C., et al (2010). hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. *Cancer*, 116(9), 2148-2158. [More Information]

Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J., et al (2010). MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU. *PLoS One*, 5(4), 1-11. [More Information]

2008

Gee, H., Camps, C., Buffa, F., Colella, S., Sheldon, H., Gleadle, J., Ragoussis, J., Harris, A. (2008). MicroRNA-10b and breast cancer metastasis. *Nature*, 455(7216), E8-E9. [More Information]